Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Manufacturing Quality United States

Pharmacy Urges US FDA To Disallow Levels Of DMF Solvent It Found In Valsartan

  • News

Executive Summary

The saga of tainted valsartan has taken another turn with an online pharmacy that tests its medications before dispensing them finding yet another probable carcinogen in lots of the blood pressure medication from multiple manufacturers. The pharmacy filed a citizen petition asking the US FDA to tighten its globally harmonized limit for the residual solvent.

 

Table

View full table

Advertisement

Related Content

Pink Sheet
House Committee Wants Answers On Foreign Inspections And Valsartan Crisis
Pink Sheet
Don't Use Recycled Raw Materials In Valsartan And Other ARBs, US FDA Says
Pink Sheet
The Reaction To Valsartan Impurities: More Scrutiny, More Testing And Tighter Limits
Pink Sheet
The Quality Lowdown: New Valsartan Lessons, The 'White Hairs’ Who Remember Viracept

Topics

Related Companies

Advertisement
Tags:
Manufacturing Quality United States
UsernamePublicRestriction

Register

PS125496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By